The Surefire Vaccine Winner Following AstraZeneca's COVID-19 Trial Pause

The Surefire Vaccine Winner Following AstraZeneca's COVID-19 Trial Pause

On Wednesday, AstraZeneca (NYSE: AZN) announced that it was pausing late-stage clinical trials of COVID-19 vaccine candidate AZD1222. A participant in the U.K. trial experienced an unexplained illness after receiving the investigational vaccine. On Saturday, AstraZeneca received a green light from U.K. regulators to resume the clinical trial.